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Abstract
Background, aim, and scope Pharmaceuticals have been
recently discussed in the press and literature regarding their
occurrence in rivers and lakes, mostly due to emissions
after use. The production of active pharmaceutical ingre-
dients (APIs) has been less analyzed for environmental
impacts. In this work, a life cycle assessment (LCA) of the
production of an API from cradle to factory gate was
carried out. The main sources of environmental impacts
were identified. The resulting environmental profile was
compared to a second pharmaceutical production and to the
production of basic chemicals.
Materials and methods Detailed production data of a
pharmaceutical production in Basel, Switzerland were used
as the basis of this work. Information about the production
of precursor chemicals was available as well. Using models
and the ecoinvent database to cover remaining data gaps, a
full life cycle inventory of the whole production was created.
Using several life cycle impact assessment methods, includ-
ing Cumulative Energy Demand (CED), Global Warming
Potential (GWP), Eco-Indicator 99 (EI99), Ecological
Scarcity 2006, and TRACI, these results were analyzed and
the main sources of environmental burdens identified.
Results Pharmaceutical production was found to have
significantly more environmental impacts than basic chem-
ical production in a kilogram-per-kilogram basis. Compared
to average basic chemical production, the API analyzed had
a CED 20 times higher, a GWP 25 times higher and an
EI99 (H/A) 17 times higher. This was expected to a degree,
as basic chemicals are much less complex molecules and
require significantly fewer chemical transformations and
purifications than pharmaceutical compounds. Between
65% and 85% of impacts were found to be caused by
energy production and use. The fraction of energy-related
impacts increased throughout the production process.
Feedstock use was another major contributor, while process
emissions not caused by energy production were only
minor contributors to the environmental impacts.
Discussion The results showed that production of APIs has
much higher impacts than basic chemical production. This
was to be expected given the increased complexity of
pharmaceutical compounds as compared with basic chem-
icals, the smaller production volumes, and the fact that API
production lines are often newer and less optimized than the
production of more established basic chemicals. The large
contributions of energy-related processes highlight the need
for a detailed assessment of energy use in pharmaceutical
production. The analysis of the energy-related contributions
to the overall impacts on a process step level allows a
comprehensive understanding of each process’ contribution
to overall impacts and their energy intensities.
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Conclusions Environmental impacts of API production
were estimated in a cradle-to-gate boundary. The major
contributors to the environmental impacts in aggregating
methods were resource consumption and emissions from
energy production. Process emissions from the pharmaceu-
tical manufacturing plant itself were less of a concern in
developed countries. Producers aiming to increase their
sustainability should increase efforts to reduce mass
intensity and to improve energy efficiency.
Recommendations and perspectives Pharmaceutical com-
panies have increased their efforts to optimize resource
efficiency and energy use in order to improve their
environmental performance. The results of this study can
be used as a first step to perform a full cradle to grave LCA
of pharmaceutical production and use, which could include
other important phases of the pharmaceutical product life
cycle. To assess a commercial pharmaceutical, the results of
API production have to be compared to the contributions of
other ingredients and formulation.
Keywords Chemical production . Energy efficiency .
Energy use . LCA of chemicals . Pharmaceuticals
1 Background, aim, and scope
The life cycles of pharmaceuticals have recently become a
concern for many environmental scientists. Many pharma-
ceutical compounds pass through the human and animal
body, and these substances and their metabolites are more
and more often encountered in the environment where they
may have harmful effects (Buser et al. 1999; Heberer 2002;
Loffler et al. 2005). In contrast, the production of
pharmaceutical compounds has not been widely analyzed
(Kummerer 2008). Few studies exist (Jiménez-Gonzalez
2000; Jiménez-Gonzalez et al. 2004), and detailed produc-
tion data on pharmaceuticals are not publicly available, as
their production parameters are usually confidential. A full
life cycle inventory (LCI) of a pharmaceutical product
would, however, be very helpful to put the effects of use
and disposal into context and to assess the environmental
impacts of the production processes against other phases of
the lifecycle, such as distribution, end-of-life, etc. Further-
more, pharmaceuticals are among the most complex
chemicals produced, and the available data on fine chemical
production are very scarce in general. Some models for
estimations of fine chemical production exist (Wernet et al.
2008, 2009), but no detailed LCI of a pharmaceutical has
been published, although some life cycle impact assessment
(LCIA) results have been made public on a comparative
rather than absolute basis. The reasons for this are, besides
the problems of confidentiality, the specialized processes
involved in the production of pharmaceuticals and other
fine chemicals. They are produced not in continuous
processes but in discreet batches, which may vary in size
from batch to batch. They are commonly produced in multi-
purpose plants (Szijjarto et al. 2008), sharing equipment
and facilities between production lines. This makes energy
inventories extremely difficult to obtain, as usage of steam
and electricity is usually measured only on a building level.
In addition, pharmaceuticals may be difficult to synthesize,
but their benefits justify unusual costs and efforts to
produce them. The chemistry of pharmaceutical production
is, therefore, often specialized and resource intensive.
Additionally, the large number of process steps may
introduce large uncertainties due to error propagation over
the production. This means that process models and
estimations which result in acceptable errors over two or
three process steps may not be applicable in fine chemical
inventories as the total error would render the result
meaningless.
The usually small production quantities in pharmaceuti-
cal production also mean that often little effort is
undertaken to optimize production. As production costs
are generally outweighed by the costs of R&D or marketing
(these often require up to 80% of the total development
costs), the economic incentive to optimize production is
lower than in the production of other chemicals. In
addition, there is less time to increase the efficiency of the
processes as time to market is crucial for pharmaceuticals.
For these reasons, processes may be more resource
intensive and less efficient than other, fully optimized
processes. An additional factor is that pharmaceuticals
often undergo formulation and purification processes after
production to ensure product purity and that the pharma-
cological function is maximized. These steps can also be
very energy and resource intensive. As resource-intensive
productions are often also environmentally problematic
(Huijbregts et al. 2006), this raises the question of the
impacts of pharmaceutical production. Mass-intensity
analyses (Sheldon 1994) are sometimes carried out in the
pharmaceutical industry. However, energy use and emissions
are not commonly assessed from a life cycle perspective.
In this work, we analyzed the full synthesis of a
pharmaceutical compound produced by F. Hoffmann-La
Roche in Basel, Switzerland. This allowed us to do a full,
“cradle-to-factory-gate” LCI of the production and thus a
LCIA of the production. We determined the impacts of
energy-related resource uses and emissions (e.g., for the
production of steam or electricity) and were thus able to
determine the relative impacts of energy production and use
compared to, e.g., feedstock uses and process emissions.
The results were compared to the internal cradle-to-gate
LCI data of another active pharmaceutical ingredient (API).
This was done to assess whether the production profile of
the analyzed pharmaceutical is similar. The LCIA results
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for this second substance had been previously published in
the literature (Jiménez-Gonzalez et al. 2004) although not
in absolute terms. The inventory data of this second API
were gathered using in-house methods (Curzons et al. 2007;
Jiménez-Gonzalez et al. 2004) and were re-evaluated for
this work to ensure that the results of this study are
comparable on a relative level.
The scope for this study was the production of the APIs
from the cradle to the substance. Galenic formulation (final
production steps of a pharmaceutical, e.g., preparation of
the pill/solution or additional steps to improve API uptake
in the body) was excluded; only the APIs themselves were
assessed. All results were based on a functional unit of 1 kg
of API. Further manufacture of the commercial products,
use phase, and end-of-life are excluded.
The results of this article offer an additional insight on
the production life cycle of pharmaceuticals, which up till
now has not been discussed in this detail in the literature.
They provide an idea of the magnitude of the environmen-
tal life cycle impacts related to API production. They are,
therefore, a useful help to LCA practitioners, especially in
the fields of medication and health.
2 Materials and methods
The name of the API is confidential; we, therefore, refer to
it as “substance A” in this paper. It is produced in ten steps
starting with cyanoacetic acid. The first five synthesis steps
happen off-site; the remaining five of the production steps
take place in a Roche plant in Basel, Switzerland. As A is a
chiral substance, two additional production steps are
required in Basel for the racemization of the unwanted
enantiomer. Data on the production in Basel was extensive.
Production documentation and measurements were provided,
including results of a mass flow analysis. These allowed a
precise determination of the mass flows for the seven
production steps in the main plant in Basel. Flows to waste
treatment facilities were also described. We used models for
waste solvent distillation (Capello et al. 2007a, 2008) and
incineration (The ecoinvent centre 2008a, b) as well as for
waste water treatment (Jodicke et al. 2001; Köhler et al.
2007) to describe the treatment processes. These efforts were
assisted by information about the specific waste treatment
options employed by Roche. In particular, measurements
were made to determine the concentration of A and
intermediates in waste water after treatment, the results of
which were made available. Energy flows were less well
documented. The production equipment is used exclusively
for the production of A, but A is produced in batches and the
plant contains several other production lines. Use of steam
and electricity was only estimated by Roche over the whole
production and then allocated to all production steps in a
simplistic manner. Therefore, these data were not used and
steam use was modeled instead of using specific models
(Capello et al. 2007b) and thermodynamic calculations. All
electricity processes are based on an average European
production (UCTE-Union for the Coordination of Transmis-
sion of Electricity). Results based on Swiss production were
calculated but are not presented here, as the very distinct
Swiss electricity mix makes comparison to average European
chemical production difficult. All these efforts were assisted
by the process engineers running the plant who offered
valuable insights and guidance. Substance A is used in
solution; therefore, the last steps include purification techni-
ques but no galenic formulation.
Less data were available on the production of the
precursor. The synthesis route was provided, but detailed
measurements of mass and energy flows were not available.
These reactions were described using publicly available
data (Thieme Chemistry 2009; Ullmann's Encyclopedia of
Industrial Chemistry 2006) and expert knowledge. The
ecoinvent database (The ecoinvent centre 2008a) was used
to supply data on starting materials and auxiliaries. Some
materials, such as bromine, were not covered by the
ecoinvent database. We gathered inventory data on these
processes from public sources and used models to complete
data gaps, e.g., bromine is generated by debromination of
bromide-rich brine. A full overview of the synthesis process
can be seen in Fig. 1. Structural formulae are shown as long
as confidentiality issues allowed it.
During the creation of all inventories, we followed a set of
standards (Hischier et al. 2004) to ensure consistency. As a
last choice in cases of missing data, we chose standard
estimations to comply with ecoinvent standards to ensure
compatibility of the data. Ecoinvent’s pedigree matrix ap-
proach (The ecoinvent centre 2008b) was applied to describe
uncertainties to allow an uncertainty analysis of the final
results. As the production of APIs is a very specialized process,
no by-products of value were generated during production—
the only exception being steam, which was reused in the
same processes as overall steam requirements were high.
We were, therefore, able to avoid allocation problems.
Energy use can often be a major source of impacts in
chemical production, and we wanted to examine whether
the same is true for pharmaceutical products. We used an
adapted version of the Brightway LCA model (Mutel and
Kestenholz 2008) to determine the impacts over the whole
production life cycle that are caused directly or indirectly
by the use and production of electricity, steam, and
transport processes. This methodology was developed to
specifically identify the fraction of the overall impacts due
to energy use over the life cycle. All resource uses and
emissions from energy processes (heat, steam, and electric-
ity) and transport processes were identified by recursively
parsing the ecoinvent database’s unit processes. All
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upstream impacts of these energy-related processes were
included as well. As the impacts of transport were minor (in
the range of less than 1 to a few percent of the overall
results), all results of the impact source analysis were
aggregated into energy-related (i.e., due to production and
use of electricity and steam and use of transport processes)
and remaining impacts (these are mostly due to feedstock
use and process emissions). Simply put, the energy-related
impacts are the impacts of all energy use processes,
including their upstream resource uses and emissions.
Correspondingly, the remaining impacts represent the
impacts of the production in a hypothetical scenario where
transport, electricity, and heat are freely available without
any requirements or negative impacts. This analysis
provides decision-aid for the producing companies on
which impacts they should focus on when improving the
production. It may also help to identify potential screening
indicators for shortcut methods in the future, which is
important because data availability is an issue concerning
pharmaceutical products.
To ascertain whether the impacts generated are some-
what representative of API production, we compared them
with the production inventory of substance B, an API
produced by GlaxoSmithKline (GSK). Relative, but not
absolute, LCIA results for API B have been published in
the literature in 2004 (Jiménez-Gonzalez et al. 2004). The
original (confidential) LCI results, rather than the LCIA
values published in 2004, were used for this study and were
analyzed and slightly updated to ensure comparability to
the assessment of A. A and B are unrelated in structure,
use, and synthesis, with the exception that both are
produced as pure enantiomers by means of an enantiomeric
separation. The production inventory of B was generated
in-house by GSK and the absolute results are confidential,
but an analysis of the composition of the environmental
impacts allowed a comparison to A.
Several LCIA methods were chosen for the environmental
assessment of the two substances. As the original inventory
data are confidential, results for a large selection of LCIA
methods were calculated and are presented here. In choosing
the methods, we aimed to cover many important areas of
environmental impacts as well as the demand for results of
aggregating methods. Resource use was represented by the
Cumulative Energy Demand (CED; Verein Deutscher
Ingenieure 1997), a method assessing the primary energy
demand of the production. This is a good indicator for
chemical production in particular, as oil and gas are both the
main energy source and the main material feedstock for
chemical production. The Global Warming Potential (GWP;
The Intergovernmental Panel on Climate Change 2007)
addresses what may be the most discussed environmental
issue of our time, and many studies require GWP data. Eco-
indicator 99 (EI99; Goedkoop and Spriensma 2000), the newer
ReCiPe (Goedkoop et al. 2009), IMPACT2002+ (Jolliet et al.
2003), Ecological Scarcity 2006 (ES2006; Frischknecht et al.
2006), and Tool for the Reduction and Assessment of
Chemical and Other Environmental Impacts (TRACI) (Bare
et al. 2003, 2006) are all methods that assess various environ-
mental impacts. EI99, IMPACT2002+, and ReCiPe offer end-
point results for a set of environmental damages and weighs
results based on the decisions of a panel of experts. ES2006 is
based on the “distance-to-political-target” principle, determin-
ing the impact of processes based on how close they come to
or exceed regulatory targets for emissions and resource uses.
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Fig. 1 Synthesis of Substance A in ten reaction steps, plus two steps for the racemization
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Tool for the Reduction and Assessment of Chemical and
Other Environmental Impacts (TRACI) assesses environmen-
tal damages with a North American perspective and provides
mid-point results. EI99 and ES2006 also offer aggregated,
single-score results. These methods were selected to cover
most areas of interest, often using various approaches,
although other methods do exist (e.g., DeWulf et al. 2007;
Rosenbaum et al. 2008; Huijbregts et al. 2008) and this list is
not meant to be fully comprehensive. For the discussion of
the results, the methods CED and EI99 were used for the
most part. Although the ReCiPe method may well replace
EI99 in the long term, we chose this method to discuss the
results here as many LCA practitioners are familiar with it.
3 Results
The results show that both the resource use and the emission
impacts of the production of the pharmaceutical A are quite
high per functional unit, reflecting the extraordinary efforts
required to produce the complex structure of the substance
and for the enantiomeric separation. Monte Carlo simulations
with 1,000 runs each were used to determine the uncertainties
of the results using the pedigree matrix approach (The eco-
invent centre 2008b), a system using data quality indicators to
qualitatively assess the reliability of the results. In this system,
results are judged to be more uncertain if the underlying data
may not describe the actual production processes well. The
CED of 1 kg of substance A is 1,430 MJ-eq/kg of substance
A, and the GWP is 67.6 kg CO2-eq/kg product. Full results
can be seen in Table 1.
The inventory data of substance B allowed a relative
comparison of the two production processes using EI99. In
general, substance B required more resources and energy
than substance A. From a chemical perspective, this was
not surprising as the synthesis of B is more complex. A
direct comparison of the data is possible, but it should be
noted that data gathering and modeling methods were not
coordinated. Especially inventory areas likely to rely on
fewer measurements and on models (e.g., aqueous emis-
sions and some air emissions) may be affected by
systematic differences. Nevertheless, Fig. 2 shows that the
EI99 impact profiles share similarities. Both productions
are very resource intensive, B even more so than A.
Analyzing the results in further detail showed that the
resource uses were almost entirely due to fossil fuel use.
The human health impacts were mostly due to global
warming and respiratory effects from inorganics. Ecosys-
LCIA method Result (standard deviation)
CED [MJ-eq/kg product] 1,430 (252)
GWP [kg CO2-eq/kg product] 67.6 (8.3)
Eco-Indicator 99 (H/A) total [points/kg product] 4.76 (0.92)
Eco-Indicator 99 (H/A) human health [points/kg product] 1.67 (0.24)
Eco-Indicator 99 (H/A) ecosystem quality [points/kg product] 0.36 (0.63)
Eco-Indicator 99 (H/A) resources [points/kg product] 2.73 (0.47)
Ecological Scarcity 2006 [Umweltbelastungspunkte/kg product] 100,000 (15,600)
TRACI smog [kg NOx-eq/kg product] 0.115 (0.018)
TRACI respiratory effects [kg PM2.5-eq/kg product] 0.113 (0.018)
TRACI global warming [kg CO2-eq/kg product] 68.6 (9.7)
TRACI ozone depletion [kg CFC-11-eq/kg product] 9.30E−6 (1.90E−6)
TRACI non-carcinogenics [kg toluene-eq/kg product] 655 (300)
TRACI eutrophication [kg N-eq/kg product] 0.152 (0.030)
TRACI ecotoxicity [kg 2,4-D-eq/kg product] 98.1 (22.7)
TRACI carcinogenics [kg benzene-eq/kg product] 0.124 (0.051)
TRACI acidification [H+ mol-eq/kg product] 21.2 (3.5)
ReCiPe (H/A) total [points/kg product] 7.01 (0.92)
ReCiPe (H/A) human health [points/kg product] 2.78 (0.48)
ReCiPe (H/A) ecosystem quality [points/kg product] 2.70 (0.33)
ReCiPe (H/A) resources [points/kg product] 1.54 (0.18)
IMPACT2002+ total [points/kg product] 2.3E−2 (3.2E−3)
IMPACT2002+ resources [points/kg product] 9.4E−3 (1.8E−3)
IMPACT2002+ human health [points/kg product] 5.9E−3 (8.1E−4)
IMPACT2002+ ecosystem quality [points/kg product] 9.6E−4 (1.8E−4)
IMPACT2002+ climate change [points/kg product] 6.7E−3 (7.8E−4)
Table 1 Results of the life
cycle impact assessment of the
pharmaceutical A
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tem quality impacts are negligible for B and small (8%) for A.
Half of these were land use impacts as an auxiliary for the
synthesis of A was produced from starch. Measurements
showed no emissions above the detection limit of A and any
intermediates after waste water treatment and air emissions
were minimal, which may explain the relatively low impacts.
The use of the Brightway model allowed an analysis of
the impact sources over the whole production life cycle of
A, separated through the classification of individual
processes into different categories. This separation is
critical for chemicals, as oil and natural gas are both the
major sources of energy and the major feedstocks for
production. Transport impacts were minimal (less than 3%
usually); therefore, transport and energy production and use
were grouped together as “energy-related” impacts. All
impacts due to these process types, including their upstream
processes, were separated from the remaining impacts.
Figure 3 shows the fractions of energy-related impacts for
several methods as they develop over the synthesis of
substance A. Energy-related impacts of A are high, over
65% for EI99 and ES2006 and over 80% for the CED and
GWP. In addition, the energy-related fraction of impacts
generally increases throughout the production. This effect is
observable for several LCIA methods, especially the CED
and GWP as well as the aggregating methods. Some impact
categories, such as Tool for the Reduction and Assessment
of Chemical and Other Environmental Impacts (TRACI)
Acidification, can be dominated by the impacts of single
processes. In these cases, no clear trend is observable. Overall,
many categories of the analyzed methods show an increase in
the fraction of energy-related impacts over the production.
Again, the EI99 results of substance Awere compared to
the results for substance B. Energy-related fractions of raw
material use and emissions were provided by GSK.
Figure 4a shows that the energy-related fraction of the
impacts of the production of B are even higher for the GWP
and ES2006 than those of A, about 20% lower for the CED
and roughly equal for EI99.
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Figure 4b shows the EI99 subcategories and the energy-
related fractions of these. The energy-related fractions of
the resources impacts are 70% for A and 59% for B. For
human health impacts, 67% for A and 91% for B are energy-
related, and for ecosystem quality, the energy-related impacts
make up 36% for A and 59% for B. The relative contri-
butions of human health and ecosystem quality impacts are
higher for A than for B. By contrast, B has higher relative
resource use impacts than A. This may be related to the
higher absolute resource use required for B, which may
dominate other impacts in a relative perspective. Among the
non-energy-related impacts for substance A, the largest
contributions are land use (required for an auxiliary) for
ecosystem quality and the aqueous emissions of the
production of phosphoric acid (required for one of the
process steps at the plant in Basel) for human health.
Unsurprisingly, the biggest resource impacts not related to
energy production and use are due to feedstock requirements.
For ES2006, resource use was only a minor factor.
Nevertheless, the production impacts are mostly energy-
related. The remaining impacts were due to process emissions.
In the case of A, most of the remaining impacts occurred
during the production of auxiliaries, which were based on
ecoinvent data. This is in agreement with the emission
measurements taken in the plant and waste treatment facility
in Basel, where harmful emissions were minimal.
4 Discussion
The results of the detailed inventory analysis of A showed a
vast difference in environmental impacts between basic
chemical production and pharmaceutical synthesis. This is
not surprising considering that API molecules are signifi-
cantly more complex than basic chemicals. In addition,
APIs require significantly more chemical transformations
and purification and require more raw materials in the
synthesis. For instance, bulk chemicals typically require
between one and two chemical transformations, while
pharmaceutical active ingredients usually require six or
more, as shown in Table 2. Each transformation adds
requirements and leads to material losses, as yields can be
as low as 70% in fine chemical production. Among
industrial chemists, the number of transformations is often
used as a rough indicator of the costs and complexities of a
production line.
The uncertainties calculated with the pedigree matrix
approach allow an assessment of the underlying data
quality. The biggest source of uncertainties were the
modeling of the precursor production, where no direct
measurements were available, and the use of ecoinvent
processes to model background processes. Nevertheless,
uncertainties are well below the actual impact scores,
usually by about an order of magnitude or a little less (see
Table 1). Considering the use of direct industry measure-
ments for the most critical steps of the production,
uncertainties were expected to be reasonably low, giving
the results a greater reliability.
The analysis revealed that the requirements and impacts
of A’s production are much larger than for most chemicals.
To put the results in context, a comparison with an analysis
of 78 basic and mass-produced organic chemicals (Wernet
et al., submitted) showed that the average CED of a basic
chemical production is only 5% of the CED of A’s
synthesis when analyzed per kilogram of product. Further-
more, the average basic chemical production impacts are
only 4% for the GWP, 6% for EI99, and 3% for ES2006
when compared to the production of A. For some
individual Tool for the Reduction and Assessment of
Chemical and Other Environmental Impacts (TRACI)
impact categories, this percentage dropped to less than
1%. After discussions with plant managers from Roche and
the comparison to substance B, the production of A was
also judged to be a rather simple representative of current
pharmaceutical synthesis. The experts agreed that many
pharmaceuticals are even more complex in their production
than substance A. This helps to put the results in Table 1
into perspective. The environmental impacts of the produc-
tion of 1 kg of A are more than one and sometimes two
orders of magnitude higher than those of an average basic
chemical production. On the other hand, the production
volumes of pharmaceuticals and other fine chemicals are
much smaller than those of many basic chemicals (see
Table 2). Pharmaceuticals are usually produced in batches of
only a few tons or even less than a ton per year. Therefore,
these higher impacts per kilogram are not necessarily
problematic when analyzed from a global perspective. This
study aims more to increase the knowledge of pharmaceu-
Industry Annual
production (tons)
Estimated total
waste—tons per annum
Typical no. of
transformations
Years of
development
Oil refining 10E06–10E08 10 million Separations 100+
Bulk chemicals 10E04–10E06 5 million 1–2 10–50
Fine chemicals 10E02–10E04 0.5 million 3–4 4–7
Pharmaceuticals 10–10E02 0.1 million ≥6 3–5
Table 2 The production of
APIs in perspective (adapted
from ACS 2008)
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tical and fine chemical production in general. In addition, it
should raise awareness of the need to analyze these systems
in a holistic manner in companies where a life cycle
approach is not yet implemented, as our results of the
detailed production analysis of substance A revealed that the
vast majority of impacts in all impact categories are due to
upstream emissions and resource uses. An environmental
analysis of just the production plant in Basel would
misrepresent the total environmental impacts of the produc-
tion both in size and composition.
The analysis of the fraction of impacts related to energy
production and use as well as transport revealed that
energy-related impacts are very relevant. Moreover, 65%
to 85% of the overall cradle-to-gate impacts of substance A
in Fig. 3 are energy-related. This shows that modern
regulatory efforts have succeeded in reducing harmful
emissions from chemical production but highlights the
additional need for a deeper analysis of energy use and
efficiency. As steam is produced on-site in Basel, green-
house gases emitted during steam production would be
counted into the emission profile of the plant. However,
other chemical sites may have different means of obtaining
steam, including nearby but external sources. This would
allow producers to shift emission burdens to other
companies when analyzing the environmental performance
on a smaller scope, e.g., plant level. Considering the
importance of impacts from energy production, this means
that a life cycle approach is necessary.
For substance B, energy is mostly used in the supply
chain. Energy use in the plant itself is only a minor
contributor (Jiménez-Gonzalez et al. 2004). For substance
A, energy use in the plant is more significant but still
between 20% and 50% of the total energy use for most
LCIA methods. It should be noted that energy-intensive
processes such as distillation can often reduce the need for
energy-demanding solvents. Therefore, the treatment meth-
od may shift the burden of the energy required for either
solvent production or recycling. The results demonstrate
that mass-intensity analysis (Sheldon 1994) may be a
valuable tool for the pharmaceutical industry but that an
additional examination of energy use is helpful to accu-
rately assess the full environmental impacts. LCA, being in
effect an extension of mass intensity analysis, offers a more
complete assessment.
Furthermore, a detailed analysis of Fig. 3 could identify
processes critical for energy use. For example, the overall
CED increases in step 6, the enantiomeric separation. Most of
the CED increase is due to energy requirements during the
process; therefore, the fraction of energy-related CED impacts
increases. However, most of the energy use is due to steam
generated with natural gas, a very efficient process. Therefore,
the GWP, which has reached a high plateau by step 4, is less
affected. In general, the fraction of energy-related impacts
increases over the production cycle for all categories shown in
Fig. 3. As energy-related impacts are similarly important for
substance B, this indicates that energy production and use
are of high relevance in fine chemical production.
Looking at the detailed EI99 analysis in Fig. 4b, the
distribution of the energy-related impacts can be deter-
mined. The majority of the resource impacts for both
substances are energy-related. In addition, energy-related
impacts play a large role for human health impacts, mostly
due to respiratory impacts and greenhouse gas emissions.
The remaining resource impacts are due to the physical
feedstock requirements of the production. The other
remaining impacts in the human health and ecosystem
quality categories are only relatively minor contributions to
the overall environmental impact. This is noteworthy as the
traditional areas of concern in chemical production, e.g.,
harmful chemical emissions from the chemical production
plant, are included in these categories. While some
concerns exist about emissions from production sites in
developing countries where oversight is low (Kummerer
2008), pharmaceutical production in developed countries
today is, therefore, less a concern due to process emissions
and more due to indirect emissions and resource consump-
tion related to energy production and use. However, this
analysis does not imply that emissions to the environment
are not relevant during later life-cycle stages.
As only the active ingredients were analyzed in this
study, it should be noted that the final formulation of
pharmaceuticals can include additional resource-intensive
steps. Other materials for pharmaceuticals often make up
the majority of the pharmaceutical by mass, but are
generally much simpler to produce. Often, final steps take
place in clean rooms, which are expensive to maintain. As
the focus of this study was the chemical synthesis, only the
production of 1 kg of API was assessed.
5 Conclusions
The LCIA results presented in Table 1 showcase the
environmental life cycle burdens of the production of a
pharmaceutical active ingredient (API). The environmental
life cycle impacts found are in line with the considerable
efforts required for the complex synthesis and the com-
plexity of pharmaceutical production, as compared to basic
chemical production. A difference of up to and sometimes
over two orders of magnitude between basic chemical and
pharmaceutical production impacts should be expected
based on the results of this study. The difference can be
explained by the greater complexity of API molecules, the
higher demands of the complex synthesis processes, and the
shorter development times of APIs, allowing less time for
optimization of the processes. Comparing impact categories
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is subjective, but for most methods applied here the largest
contributors to environmental burdens were the resource
impacts and the emissions of greenhouse gases. For most of
the methods used and categories analyzed, a majority (and
sometimes up to 85%) of the impacts were directly or
indirectly caused by energy use. Process emissions from
chemical plants and transport were only minor contributors
to the overall impacts. This leads to the conclusion that
modern emission controls in developed countries are
largely effective, at least barring major accidents. The
environmental profiles of the two API systems analyzed
were in general comparable, given the differences in
complexity of the two materials and synthesis and the
inherent uncertainty of the LCA estimations. Furthermore,
the analysis suggests that optimizations in material and
energy efficiency are the most effective ways of increasing
the sustainability of modern fine chemical production.
The low required production volumes of pharmaceut-
icals and their obvious benefits to society justify these
environmental impacts, but nevertheless this study has led
us to suggest to an increased optimization of materials and
energy use in production. The results can assist environ-
mentally beneficial process optimizations.
6 Recommendations and perspectives
Our analysis showed that pharmaceutical production is
significantly more complex than basic chemical production.
Even the two substances in this study showed large differ-
ences in their absolute impacts, to a degree that using the data
of one to approximate the other would lead to errors. This
variation is explained by the significant differences in
complexity of the molecule and the synthetic process and
uncertainties in the LCA models. Additional LCA studies
and publicly available LCI data are needed to improve LCA
results of processes and products requiring fine chemicals.
While fine chemicals are often produced and used in
lower quantities, their lower contribution in mass to
consumer and industrial products should not lead LCA
practitioners to neglect their importance. The data in this
study may serve as a proxy to carry out a sensitivity
analysis of environmental life cycle impacts of fine
chemicals in other LCA studies to assess the relative
importance of their impacts and to determine whether
additional data have to be gathered.
In addition, although some cradle-to-gate assessments of
API production systems have been completed to date, further
research is needed both to specifically address the open
questions on fine chemical production and for the eventual
full cradle-to-grave LCA studies of pharmaceutical products,
for which production data are vital. Additional production
studies would help put into perspective the true environ-
mental life cycle of medicine production. Until this date, it is
uncertain how much of the life cycle environmental impacts
of medicine production can be attributed to the API and how
much is contributed by downstream impacts.
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